Directorio

In this study, patients will first receive either the study drug or a placebo for 24 weeks. After that, everyone in the study will receive the real drug for 28 weeks. The whole study will last about 60 weeks. Each person will need to come to the clinic nine times during the study. All visits will take place at the South Durham Clinic.

In this study, you will take a medicine called ALTA3263 by mouth every day. You will keep taking it until your cancer gets worse or until you need to stop because of strong or frequent side effects. While you are in the study, you will go to the clinic for regular visits. During these visits, the study team will do tests to check your health and collect information for research.

We are doing this study to find out if an investigational gene therapy drug called ABBV-RGX-314 (the study drug) is a safe and effective option for people with diabetic retinopathy. The study drug is delivered directly into the suprachoroidal space of the eye using a technology called Microinjector®, which is an experimental needle device.

We are doing this study to find out if an experimental drug called ALXN2030 (the study drug) is a safe and effective option for people diagnosed with antibody-mediated rejection (AMR) of a transplanted kidney.

We are doing this study to compare how safe and effective different drug combinations are for treating metastatic cancer.